Plasma Epstein-Barr virus DNA screening followed by 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

Plasma Epstein-Barr virus DNA screening followed by 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma

Published:2011-03-22 Issue:19 Volume:117 Page:4452-4459
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wang Wen-Yi,Twu Chih-Wen,Lin Wan-Yu,Jiang Rong-San,Liang Kai-Li,Chen Kuan-Wen,Wu Ching-Te,Shih Yi-Ting,Lin Jin-Ching

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. Nasopharyngeal carcinoma staging by F-fluorodeoxyglucose positron emission tomography;Chang;Int J Radiat Oncol Biol Phys.,2006

2. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis;King;Br J Radiol.,2008

3. [18F] Fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging;Liu;J Clin Oncol.,2006

4. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma;Liu;J Nucl Med.,2007

5. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma;Chua;Head Neck.,2009

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial;Nature Communications;2024-01-31

2. Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma;Future Oncology;2023-11-01

3. The Clinical Application of Plasma EBV DNA Assay in NPC;Medical Radiology;2023

4. Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load;Oral Oncology;2022-11

5. Association of delayed chemoradiotherapy with elevated Epstein-Barr virus DNA load and adverse clinical outcome in nasopharyngeal carcinoma treatment during the COVID-19 pandemic: a retrospective study;Cancer Cell International;2022-10-31